1|Page
NAPSR CNPR EXAM/NAPSR CNPR Final Exam
Newest Exam Preparation With Complete Questions
And Correct Answers With Rationales | Already
Graded A+||Brand New Version!!
1.
Pharmaceuticals are arguably the most socially important healthcare
product because they:
A) Generate the highest revenue of any healthcare sector
B) Directly prevent, treat, and cure diseases while improving quality of
life
C) Require the most extensive regulatory oversight
D) Have the longest development timelines of any product category
Answer: B
Explanation: Pharmaceuticals hold profound social importance because
they directly impact human health by preventing, treating, and curing
diseases, thereby extending life expectancy and improving quality of
life. While pharmaceutical companies do generate substantial revenue
(A) and face extensive regulation (C) with long development timelines
(D), these are consequences of their social importance rather than the
,2|Page
defining reason for it. The fundamental value of pharmaceuticals lies in
their therapeutic benefit to patients and society.
2.
Pharmaceutical development is considered a high-risk undertaking
primarily because:
A) Manufacturing costs are prohibitively expensive
B) Many promising drug candidates fail during clinical trials or prove
ineffective
C) Regulatory approval takes too long
D) Marketing expenses exceed research costs
Answer: B
Explanation: The pharmaceutical development process is inherently
risky because the vast majority of drug candidates—often more than
90%—fail during clinical trials or prove ineffective in humans despite
promising preclinical results. While manufacturing costs (A), regulatory
timelines (C), and marketing expenses (D) are significant factors, the
primary risk is scientific and clinical failure, which results in the loss of
substantial research and development investments without any
marketable product.
3.
The term "pharmacovigilance" refers to:
A) The process of discovering new drug molecules
,3|Page
B) The science of drug dosing based on patient weight
C) The monitoring of drug safety and adverse effects after market
approval
D) The legal protection of pharmaceutical patents
Answer: C
Explanation: Pharmacovigilance is the pharmacological science relating
to the collection, detection, assessment, monitoring, and prevention of
adverse effects with pharmaceutical products. It is a post-marketing
surveillance activity that continues throughout a drug's lifecycle.
Discovery (A) is drug discovery, dosing science (B) is
pharmacokinetics/pharmacodynamics, and patent protection (D) is
intellectual property law, none of which define pharmacovigilance.
4.
Which of the following best defines a "blockbuster" drug?
A) A drug that has been approved by the FDA on the first review cycle
B) A drug that generates annual sales exceeding one billion dollars
C) A drug that treats multiple disease indications
D) A drug that has no generic competition
Answer: B
, 4|Page
Explanation: In the pharmaceutical industry, the term "blockbuster" is
conventionally applied to drugs that achieve annual global sales of over
one billion dollars. While such drugs often receive fast approval (A), may
treat multiple indications (C), and frequently have strong patent
protection (D), these characteristics are not defining criteria. The
classification is strictly based on revenue generation, reflecting the
drug's commercial success and market penetration.
5.
The "patent cliff" refers to:
A) The period when a new drug patent is filed and pending review
B) The sharp decline in revenue when a drug loses patent protection
and generics enter the market
C) The regulatory hurdle for biosimilar approval
D) The expiration of clinical trial exclusivity
Answer: B
Explanation: The patent cliff is a term used to describe the precipitous
drop in revenue that pharmaceutical companies experience when their
patented drugs lose exclusivity and face generic competition. Generic
competitors, which are chemically identical and therapeutically
equivalent, typically enter the market at significantly lower prices,
capturing substantial market share. The cliff is not the filing period (A),
a biosimilar hurdle (C), or trial exclusivity (D), but the economic
consequence of patent expiration.
NAPSR CNPR EXAM/NAPSR CNPR Final Exam
Newest Exam Preparation With Complete Questions
And Correct Answers With Rationales | Already
Graded A+||Brand New Version!!
1.
Pharmaceuticals are arguably the most socially important healthcare
product because they:
A) Generate the highest revenue of any healthcare sector
B) Directly prevent, treat, and cure diseases while improving quality of
life
C) Require the most extensive regulatory oversight
D) Have the longest development timelines of any product category
Answer: B
Explanation: Pharmaceuticals hold profound social importance because
they directly impact human health by preventing, treating, and curing
diseases, thereby extending life expectancy and improving quality of
life. While pharmaceutical companies do generate substantial revenue
(A) and face extensive regulation (C) with long development timelines
(D), these are consequences of their social importance rather than the
,2|Page
defining reason for it. The fundamental value of pharmaceuticals lies in
their therapeutic benefit to patients and society.
2.
Pharmaceutical development is considered a high-risk undertaking
primarily because:
A) Manufacturing costs are prohibitively expensive
B) Many promising drug candidates fail during clinical trials or prove
ineffective
C) Regulatory approval takes too long
D) Marketing expenses exceed research costs
Answer: B
Explanation: The pharmaceutical development process is inherently
risky because the vast majority of drug candidates—often more than
90%—fail during clinical trials or prove ineffective in humans despite
promising preclinical results. While manufacturing costs (A), regulatory
timelines (C), and marketing expenses (D) are significant factors, the
primary risk is scientific and clinical failure, which results in the loss of
substantial research and development investments without any
marketable product.
3.
The term "pharmacovigilance" refers to:
A) The process of discovering new drug molecules
,3|Page
B) The science of drug dosing based on patient weight
C) The monitoring of drug safety and adverse effects after market
approval
D) The legal protection of pharmaceutical patents
Answer: C
Explanation: Pharmacovigilance is the pharmacological science relating
to the collection, detection, assessment, monitoring, and prevention of
adverse effects with pharmaceutical products. It is a post-marketing
surveillance activity that continues throughout a drug's lifecycle.
Discovery (A) is drug discovery, dosing science (B) is
pharmacokinetics/pharmacodynamics, and patent protection (D) is
intellectual property law, none of which define pharmacovigilance.
4.
Which of the following best defines a "blockbuster" drug?
A) A drug that has been approved by the FDA on the first review cycle
B) A drug that generates annual sales exceeding one billion dollars
C) A drug that treats multiple disease indications
D) A drug that has no generic competition
Answer: B
, 4|Page
Explanation: In the pharmaceutical industry, the term "blockbuster" is
conventionally applied to drugs that achieve annual global sales of over
one billion dollars. While such drugs often receive fast approval (A), may
treat multiple indications (C), and frequently have strong patent
protection (D), these characteristics are not defining criteria. The
classification is strictly based on revenue generation, reflecting the
drug's commercial success and market penetration.
5.
The "patent cliff" refers to:
A) The period when a new drug patent is filed and pending review
B) The sharp decline in revenue when a drug loses patent protection
and generics enter the market
C) The regulatory hurdle for biosimilar approval
D) The expiration of clinical trial exclusivity
Answer: B
Explanation: The patent cliff is a term used to describe the precipitous
drop in revenue that pharmaceutical companies experience when their
patented drugs lose exclusivity and face generic competition. Generic
competitors, which are chemically identical and therapeutically
equivalent, typically enter the market at significantly lower prices,
capturing substantial market share. The cliff is not the filing period (A),
a biosimilar hurdle (C), or trial exclusivity (D), but the economic
consequence of patent expiration.
